Literature DB >> 12621310

Neuroprotective and nootropic actions of a novel cyclized dipeptide after controlled cortical impact injury in mice.

Alan I Faden1, Gerard B Fox, Xiao Di, Susan M Knoblach, Ibolja Cernak, Paul Mullins, Maria Nikolaeva, Alan P Kozikowski.   

Abstract

1-ARA-35b (35b) is a cyclized dipeptide that shows considerable neuroprotective activity in vitro and improves neurologic recovery after fluid percussion-induced traumatic brain injury in rats. The authors evaluated the effects of treatment with 35b in mice subjected to controlled cortical impact brain injury. Animals treated with intravenous 35b after traumatic injury showed significantly enhanced recovery of beam walking and place learning functions compared with vehicle-treated controls, in addition to reduced lesion volumes. Beneficial effects were dose related and showed an inverted U-shaped dose-response curve between 0.1 and 10 mg/kg. Protective actions were found when the drug was administered initially at 30 minutes or 1, 4, or 8 hours, but not at 24 hours, after trauma. In separate experiments, rats treated with 35b on days 7 through 10 after injury showed remarkably improved place learning in comparison with injured controls. These studies confirm and extend the neuroprotective effects of this diketopiperazine in traumatic brain injury. In addition, they show that 35b has a relatively wide therapeutic window and improves cognitive function after both acute and chronic injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621310     DOI: 10.1097/01.WCB.0000046144.31247.33

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  17 in total

1.  CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury.

Authors:  Shruti V Kabadi; Bogdan A Stoica; Marie Hanscom; David J Loane; Giorgi Kharebava; Michael G Murray Ii; Rainier M Cabatbat; Alan I Faden
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 2.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

Review 3.  Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies.

Authors:  Alexander G Yakovlev; Alan I Faden
Journal:  NeuroRx       Date:  2004-01

4.  Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma.

Authors:  Shruti V Kabadi; Bogdan A Stoica; Kimberly R Byrnes; Marie Hanscom; David J Loane; Alan I Faden
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-10       Impact factor: 6.200

Review 5.  Neuroprotection for traumatic brain injury.

Authors:  David J Loane; Bogdan A Stoica; Alan I Faden
Journal:  Handb Clin Neurol       Date:  2015

Review 6.  Animal models of head trauma.

Authors:  Ibolja Cernak
Journal:  NeuroRx       Date:  2005-07

7.  Inhibition of Nogo-66 receptor 1 enhances recovery of cognitive function after traumatic brain injury in mice.

Authors:  Jing Tong; Weimin Liu; Xiaowei Wang; Xiaodi Han; Ollivier Hyrien; Uzma Samadani; Douglas H Smith; Jason H Huang
Journal:  J Neurotrauma       Date:  2013-02-04       Impact factor: 5.269

8.  Comparing the predictive value of multiple cognitive, affective, and motor tasks after rodent traumatic brain injury.

Authors:  Zaorui Zhao; David J Loane; Michael G Murray; Bogdan A Stoica; Alan I Faden
Journal:  J Neurotrauma       Date:  2012-08-27       Impact factor: 5.269

9.  In vivo production of artificial nonribosomal peptide products in the heterologous host Escherichia coli.

Authors:  Stephan Gruenewald; Henning D Mootz; Per Stehmeier; Torsten Stachelhaus
Journal:  Appl Environ Microbiol       Date:  2004-06       Impact factor: 4.792

Review 10.  Multifunctional drug treatment in neurotrauma.

Authors:  Bogdan Stoica; Kimberly Byrnes; Alan I Faden
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.